Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
359948 | IRF2BP2 | GSM5252128_BPH327PrGF_Via | Human | Prostate | BPH | 3.44e-17 | 8.58e-01 | -0.1688 |
359948 | IRF2BP2 | GSM5252129_BPH327PrSF_Via | Human | Prostate | BPH | 6.96e-09 | 8.00e-01 | -0.1697 |
359948 | IRF2BP2 | GSM5252131_BPH340PrSF_Via | Human | Prostate | BPH | 6.18e-07 | 5.80e-01 | -0.2126 |
359948 | IRF2BP2 | GSM5252132_BPH389PrGF | Human | Prostate | BPH | 2.21e-02 | 9.27e-01 | -0.2247 |
359948 | IRF2BP2 | GSM5252134_BPH511PrG_Fcol_3GEX | Human | Prostate | BPH | 4.51e-04 | 5.38e-01 | -0.1433 |
359948 | IRF2BP2 | GSM5252135_BPH511PrPUr_Fcol_3GEX | Human | Prostate | BPH | 1.79e-09 | 7.00e-01 | -0.1833 |
359948 | IRF2BP2 | GSM5252137_BPH556PrGA2_Fcol | Human | Prostate | BPH | 2.40e-07 | 1.16e+00 | -0.23 |
359948 | IRF2BP2 | 047563_1562-all-cells | Human | Prostate | BPH | 1.14e-22 | -3.60e-01 | 0.0791 |
359948 | IRF2BP2 | 048752_1579-all-cells | Human | Prostate | BPH | 1.31e-06 | -8.69e-02 | 0.1008 |
359948 | IRF2BP2 | 052097_1595-all-cells | Human | Prostate | BPH | 3.38e-06 | -1.69e-01 | 0.0972 |
359948 | IRF2BP2 | Dong_P1 | Human | Prostate | Tumor | 1.32e-31 | -4.68e-02 | 0.035 |
359948 | IRF2BP2 | Dong_P3 | Human | Prostate | Tumor | 4.51e-20 | -2.37e-01 | 0.0278 |
359948 | IRF2BP2 | Dong_P4 | Human | Prostate | Tumor | 1.12e-05 | -2.42e-01 | 0.0292 |
359948 | IRF2BP2 | Dong_P5 | Human | Prostate | Tumor | 1.96e-35 | -2.06e-01 | 0.053 |
359948 | IRF2BP2 | Dong_P6 | Human | Prostate | Tumor | 3.20e-02 | -4.29e-01 | 0.0371 |
359948 | IRF2BP2 | GSM5353240_PA_PR5254_T1_S15_L001 | Human | Prostate | Tumor | 6.60e-04 | -3.16e-01 | 0.1575 |
359948 | IRF2BP2 | GSM5353243_PA_PR5261_T1_S23_L002 | Human | Prostate | Tumor | 1.94e-11 | -2.53e-01 | 0.1545 |
359948 | IRF2BP2 | GSM5353244_PA_PR5261_T2_S24_L002 | Human | Prostate | Tumor | 1.57e-03 | -5.23e-02 | 0.1569 |
359948 | IRF2BP2 | P4_S8_cSCC | Human | Skin | cSCC | 1.29e-10 | 8.09e-02 | -0.3095 |
359948 | IRF2BP2 | P5_S10_cSCC | Human | Skin | cSCC | 1.36e-08 | -2.70e-01 | -0.299 |
Tissue | Expression Dynamics | Abbreviation |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/IRF2BP2_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/IRF2BP2_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/IRF2BP2_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/IRF2BP2_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/IRF2BP2_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/IRF2BP2_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/IRF2BP2_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/IRF2BP2_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:1903131 | Colorectum | FAP | mononuclear cell differentiation | 79/2622 | 426/18723 | 5.00e-03 | 3.33e-02 | 79 |
GO:19031317 | Esophagus | ESCC | mononuclear cell differentiation | 226/8552 | 426/18723 | 1.20e-03 | 5.88e-03 | 226 |
GO:00300984 | Esophagus | ESCC | lymphocyte differentiation | 192/8552 | 374/18723 | 1.52e-02 | 4.93e-02 | 192 |
GO:19031316 | Oral cavity | OSCC | mononuclear cell differentiation | 210/7305 | 426/18723 | 8.44e-06 | 9.02e-05 | 210 |
GO:00300983 | Oral cavity | OSCC | lymphocyte differentiation | 179/7305 | 374/18723 | 2.74e-04 | 1.74e-03 | 179 |
GO:190313114 | Oral cavity | EOLP | mononuclear cell differentiation | 88/2218 | 426/18723 | 1.07e-07 | 3.61e-06 | 88 |
GO:003009812 | Oral cavity | EOLP | lymphocyte differentiation | 76/2218 | 374/18723 | 1.50e-06 | 3.55e-05 | 76 |
GO:00421132 | Oral cavity | EOLP | B cell activation | 61/2218 | 334/18723 | 3.68e-04 | 3.35e-03 | 61 |
GO:190313122 | Oral cavity | NEOLP | mononuclear cell differentiation | 77/2005 | 426/18723 | 2.80e-06 | 6.41e-05 | 77 |
GO:003009821 | Oral cavity | NEOLP | lymphocyte differentiation | 66/2005 | 374/18723 | 3.08e-05 | 4.67e-04 | 66 |
GO:0030183 | Oral cavity | NEOLP | B cell differentiation | 25/2005 | 141/18723 | 7.85e-03 | 3.90e-02 | 25 |
GO:19031315 | Prostate | BPH | mononuclear cell differentiation | 98/3107 | 426/18723 | 3.43e-04 | 2.55e-03 | 98 |
GO:00300982 | Prostate | BPH | lymphocyte differentiation | 83/3107 | 374/18723 | 2.76e-03 | 1.46e-02 | 83 |
GO:190313113 | Prostate | Tumor | mononuclear cell differentiation | 102/3246 | 426/18723 | 2.87e-04 | 2.32e-03 | 102 |
GO:003009811 | Prostate | Tumor | lymphocyte differentiation | 87/3246 | 374/18723 | 1.93e-03 | 1.12e-02 | 87 |
GO:19031319 | Thyroid | HT | mononuclear cell differentiation | 54/1272 | 426/18723 | 6.88e-06 | 2.00e-04 | 54 |
GO:00300986 | Thyroid | HT | lymphocyte differentiation | 47/1272 | 374/18723 | 3.32e-05 | 7.02e-04 | 47 |
GO:00421133 | Thyroid | HT | B cell activation | 39/1272 | 334/18723 | 6.66e-04 | 7.61e-03 | 39 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
IRF2BP2 | SNV | Missense_Mutation | novel | c.1198N>A | p.Pro400Thr | p.P400T | Q7Z5L9 | protein_coding | deleterious(0.04) | probably_damaging(0.915) | TCGA-BH-A0B6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
IRF2BP2 | insertion | Frame_Shift_Ins | novel | c.1166_1167insTTACCCTGAAACATTG | p.Pro390TyrfsTer32 | p.P390Yfs*32 | Q7Z5L9 | protein_coding | | | TCGA-A2-A0CQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
IRF2BP2 | insertion | Frame_Shift_Ins | novel | c.1345_1346insT | p.Ser449PhefsTer7 | p.S449Ffs*7 | Q7Z5L9 | protein_coding | | | TCGA-A2-A0CU-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD |
IRF2BP2 | insertion | Frame_Shift_Ins | novel | c.1389dupT | p.Met464TyrfsTer81 | p.M464Yfs*81 | Q7Z5L9 | protein_coding | | | TCGA-A8-A06R-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | 5-fluorouracil | CR |
IRF2BP2 | insertion | Nonsense_Mutation | novel | c.1519_1520insGAAAAACCCAATGATT | p.Thr507ArgfsTer5 | p.T507Rfs*5 | Q7Z5L9 | protein_coding | | | TCGA-A8-A07R-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Ancillary | zoledronic | SD |
IRF2BP2 | SNV | Missense_Mutation | novel | c.1708N>A | p.Glu570Lys | p.E570K | Q7Z5L9 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-C5-A8YQ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | PD |
IRF2BP2 | SNV | Missense_Mutation | novel | c.1232G>A | p.Arg411Gln | p.R411Q | Q7Z5L9 | protein_coding | tolerated(0.06) | benign(0.253) | TCGA-AA-3994-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | capecitabine | CR |
IRF2BP2 | SNV | Missense_Mutation | | c.1395N>G | p.Asn465Lys | p.N465K | Q7Z5L9 | protein_coding | tolerated(0.1) | possibly_damaging(0.549) | TCGA-AZ-4681-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
IRF2BP2 | SNV | Missense_Mutation | | c.1535N>T | p.Arg512Leu | p.R512L | Q7Z5L9 | protein_coding | deleterious(0) | probably_damaging(0.967) | TCGA-G4-6628-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
IRF2BP2 | SNV | Missense_Mutation | novel | c.1120N>A | p.Gly374Arg | p.G374R | Q7Z5L9 | protein_coding | deleterious(0.02) | probably_damaging(0.978) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |